Structure Therapeutics Advances Weight-Loss Pill with 11.3% Weight Loss in 36 Weeks
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 17h ago
0mins
Source: Benzinga
- Clinical Trial Results: In the core Phase 2b ACCESS study, Structure Therapeutics' aleniglipron achieved a clinically significant weight loss of 11.3% over 36 weeks, indicating its potential in the weight-loss drug market and likely attracting more patient interest.
- Adverse Event Monitoring: The study reported a treatment discontinuation rate of 10.4% for aleniglipron, suggesting that while weight loss results are promising, managing side effects is crucial for ensuring long-term patient adherence and safety.
- Market Challenges: The CEO warned that unapproved alternatives could undermine market entry for new drugs, especially when demand exceeds supply, highlighting the urgent need for regulatory measures to protect the market share of new medications.
- Future Research Plans: Structure Therapeutics is conducting three new clinical studies for aleniglipron to gather additional data that will support its Phase 3 program and position the company favorably in the competitive weight-loss drug market.
Analyst Views on GPCR
Wall Street analysts forecast GPCR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GPCR is 74.00 USD with a low forecast of 50.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
10 Buy
0 Hold
0 Sell
Strong Buy
Current: 84.330
Low
50.00
Averages
74.00
High
100.00
Current: 84.330
Low
50.00
Averages
74.00
High
100.00
About GPCR
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
